glp-1 agonists weight loss drugs market Glucagon-Like Peptide (GLP)-1 Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer GLP-1 Medications for Weight Loss:

Sorli, C., Harashima, S., Tsoukas, G

Physiol Rep 2015;3:e12610

Monlunabant is a small molecule that blocks CB1 receptors, which is intended for oral administration

Novo Nordisk also continues to face competition from compounding pharmacies that sell discounted, knock-off versions of semaglutide, the active ingredient in Wegovy and Ozempic

Bourla said that even when the drugmaker was negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs currently dominated by Eli Lilly and Co and Novo Nordisk to get so big, so fast